JP2007500233A - β2アドレナリン作動性レセプターアゴニストの結晶形態 - Google Patents

β2アドレナリン作動性レセプターアゴニストの結晶形態 Download PDF

Info

Publication number
JP2007500233A
JP2007500233A JP2006533430A JP2006533430A JP2007500233A JP 2007500233 A JP2007500233 A JP 2007500233A JP 2006533430 A JP2006533430 A JP 2006533430A JP 2006533430 A JP2006533430 A JP 2006533430A JP 2007500233 A JP2007500233 A JP 2007500233A
Authority
JP
Japan
Prior art keywords
hydroxy
compound
solution
phenyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007500233A5 (cg-RX-API-DMAC10.html
Inventor
イオンナ スタージャデス,
エドワード ヨースト,
クリスティン ハバード,
ウェイジャン チャン,
Original Assignee
セラヴァンス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス インコーポレーテッド filed Critical セラヴァンス インコーポレーテッド
Publication of JP2007500233A publication Critical patent/JP2007500233A/ja
Publication of JP2007500233A5 publication Critical patent/JP2007500233A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006533430A 2003-05-27 2004-05-26 β2アドレナリン作動性レセプターアゴニストの結晶形態 Pending JP2007500233A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47342303P 2003-05-27 2003-05-27
PCT/US2004/016602 WO2004106279A2 (en) 2003-05-27 2004-05-26 CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST

Publications (2)

Publication Number Publication Date
JP2007500233A true JP2007500233A (ja) 2007-01-11
JP2007500233A5 JP2007500233A5 (cg-RX-API-DMAC10.html) 2007-07-05

Family

ID=33490599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533430A Pending JP2007500233A (ja) 2003-05-27 2004-05-26 β2アドレナリン作動性レセプターアゴニストの結晶形態

Country Status (19)

Country Link
US (3) US7557247B2 (cg-RX-API-DMAC10.html)
EP (1) EP1641744A2 (cg-RX-API-DMAC10.html)
JP (1) JP2007500233A (cg-RX-API-DMAC10.html)
KR (1) KR20060017616A (cg-RX-API-DMAC10.html)
CN (1) CN100528835C (cg-RX-API-DMAC10.html)
AR (1) AR045317A1 (cg-RX-API-DMAC10.html)
AU (1) AU2004243304A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0410705A (cg-RX-API-DMAC10.html)
CA (1) CA2525839A1 (cg-RX-API-DMAC10.html)
CO (1) CO5650226A2 (cg-RX-API-DMAC10.html)
IS (1) IS8111A (cg-RX-API-DMAC10.html)
MA (1) MA27779A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05012678A (cg-RX-API-DMAC10.html)
NO (1) NO20056132L (cg-RX-API-DMAC10.html)
NZ (1) NZ543355A (cg-RX-API-DMAC10.html)
RU (1) RU2005140652A (cg-RX-API-DMAC10.html)
TW (1) TW200510277A (cg-RX-API-DMAC10.html)
WO (1) WO2004106279A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200510104B (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
TW200526547A (en) * 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
EP1730104A1 (en) 2004-04-02 2006-12-13 Glaxo Group Limited Chemical process and new crystalline form
EP1786762A2 (en) * 2004-09-10 2007-05-23 Theravance, Inc. Amidine substituted aryl aniline compounds
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US8420286B2 (en) * 2008-03-27 2013-04-16 Xerox Corporation Toner process
US8367294B2 (en) * 2008-03-27 2013-02-05 Xerox Corporation Toner process
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5791983A (en) * 1980-10-01 1982-06-08 Glaxo Group Ltd Ranitidine, manufacture and medicinal composition containing same
JPH07316141A (ja) * 1986-08-05 1995-12-05 Richter Gedeon V G Rt 形態学的に均質型のチアゾール誘導体の製造方法
WO2001042193A1 (en) * 1999-12-08 2001-06-14 Theravance, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2003042164A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US676793A (en) * 1899-09-12 1901-06-18 A D Fenwick Machine Co Pasting-machine for collars, &c.
US654117A (en) * 1899-11-29 1900-07-17 Henry B Maddocks Coal-bucket.
US4064125A (en) * 1976-10-29 1977-12-20 E. R. Squibb And Sons, Inc. Substituted amides having antiinflammatory activity
US5290815A (en) 1989-09-07 1994-03-01 Glaxo Group Limited Treatment of inflammation and allergy
US5872126A (en) 1996-09-06 1999-02-16 Merck & Co., Inc. Methods and compositions for treating preterm labor
GB9713819D0 (en) 1997-06-30 1997-09-03 Glaxo Group Ltd Method of reducing the systemic effects of compounds
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6350738B1 (en) * 1998-03-06 2002-02-26 Brigham Young University Steroid derived antibiotics
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ グループ リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US8501994B2 (en) * 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5791983A (en) * 1980-10-01 1982-06-08 Glaxo Group Ltd Ranitidine, manufacture and medicinal composition containing same
JPH07316141A (ja) * 1986-08-05 1995-12-05 Richter Gedeon V G Rt 形態学的に均質型のチアゾール誘導体の製造方法
WO2001042193A1 (en) * 1999-12-08 2001-06-14 Theravance, Inc. β2-ADRENERGIC RECEPTOR AGONISTS
WO2003042164A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists

Also Published As

Publication number Publication date
CA2525839A1 (en) 2004-12-09
AU2004243304A1 (en) 2004-12-09
WO2004106279A2 (en) 2004-12-09
MXPA05012678A (es) 2006-02-22
NZ543355A (en) 2009-06-26
RU2005140652A (ru) 2006-04-20
NO20056132L (no) 2006-01-26
CN1795169A (zh) 2006-06-28
US20100125150A1 (en) 2010-05-20
MA27779A1 (fr) 2006-02-01
CO5650226A2 (es) 2006-06-30
AR045317A1 (es) 2005-10-26
US20040248985A1 (en) 2004-12-09
KR20060017616A (ko) 2006-02-24
BRPI0410705A (pt) 2006-06-13
US7557247B2 (en) 2009-07-07
IS8111A (is) 2005-10-31
WO2004106279A3 (en) 2005-02-03
ZA200510104B (en) 2006-11-29
US20070155990A1 (en) 2007-07-05
EP1641744A2 (en) 2006-04-05
CN100528835C (zh) 2009-08-19
TW200510277A (en) 2005-03-16
US7772434B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
US7772434B2 (en) Crystalline form of a β2 adrenergic receptor agonist
US20050075271A1 (en) Crystalline beta2 adrenergic receptor agonist
JP5041814B2 (ja) β2アドレナリン作用性レセプターアゴニストとしてのアリールアニリン誘導体
US6747043B2 (en) Alkoxy aryl β2 adrenergic receptor agonists
EP1641465B1 (en) Combinations of an aryl aniline beta-2 adrenergic receptor agonist and a corticosteroid
US7399863B2 (en) Amino-substituted ethylamino β2 adrenergic receptor agonists
US7060712B2 (en) Crystalline form of aryl aniline β2 adrenergic receptor agonist
JP2008512470A (ja) アミジン置換アリールアニリン化合物
TW201517907A (zh) 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽
CN101137625A (zh) β2肾上腺素能激动剂的肉桂酸盐
HK1093486B (en) Amino-substituted ethylamino beta2 adrenergic receptor agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110303

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110303